NMRA (Neumora Therapeutics, Inc. Common Stock) Stock Financials & Earnings

NMRANeumora Therapeutics, Inc. Common Stock

Mkt Cap$586M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$236M

EPS (TTM)-$1.47

Free Cash Flow (TTM)-$209M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q4 2025 · Mar 16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$31M
Q1 23	$0	$0	-$39M
Q2 23	$0	$0	-$42M
Q3 23	$0	$0	-$57M
Q4 23	$0	-$166K	-$50M
Q1 24	$0	$0	-$60M
Q2 24	$0	$0	-$64M
Q3 24	$0	$0	-$77M
Q4 24	$0	$0	-$63M
Q1 25	$0	$0	-$71M
Q2 25	$0	$0	-$54M
Q3 25	$0	-$5M	-$58M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$24M	$7M	—
Q1 23	$29M	$10M	—
Q2 23	$33M	$9M	—
Q3 23	$42M	$15M	—
Q4 23	$39M	—	$11M
Q1 24	$46M	$14M	—
Q2 24	$49M	$15M	—
Q3 24	$61M	$16M	—
Q4 24	$46M	$17M	—
Q1 25	$52M	$19M	—
Q2 25	$39M	$15M	—
Q3 25	$41M	$12M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$241M	$131M	$372M
Q1 23	$211M	$135M	$346M
Q2 23	$204M	$120M	$324M
Q3 23	$412M	$97M	$510M
Q4 23	$374M	$80M	$454M
Q1 24	$183M	$240M	$423M
Q2 24	$151M	$221M	$372M
Q3 24	$276M	$66M	$341M
Q4 24	$142M	$165M	$308M
Q1 25	$127M	$122M	$249M
Q2 25	$125M	$93M	$218M
Q3 25	$129M	$42M	$172M

Shares Outstanding

Revenue Per Employee

Revenue / Employee